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Lipoxygenases (LOXs) are dioxygenases that catalyze the formation of corresponding hydroperoxides
from polyunsaturated fatty acids such as linoleic acid and arachidonic acid. LOX enzymes are expressed
in immune, epithelial, and tumor cells that display a variety of physiological functions, including in-
ﬂammation, skin disorder, and tumorigenesis. In the humans and mice, six LOX isoforms have been
known. 15-LOX, a prototypical enzyme originally found in reticulocytes shares the similarity of amino
acid sequence as well as the biochemical property to plant LOX enzymes. 15-LOX-2, which is expressed in
epithelial cells and leukocytes, has different substrate speciﬁcity in the humans and mice, therefore, the
role of them in mammals has not been established. 12-LOX is an isoform expressed in epithelial cells and
myeloid cells including platelets. Many mutations in this isoform are found in epithelial cancers, sug-
gesting a potential link between 12-LOX and tumorigenesis. 12R-LOX can be found in the epithelial cells
of the skin. Defects in this gene result in ichthyosis, a cutaneous disorder characterized by pathophy-
siologically dried skin due to abnormal loss of water from its epithelial cell layer. Similarly, eLOX-3, which
is also expressed in the skin epithelial cells acting downstream 12R-LOX, is another causative factor for
ichthyosis. 5-LOX is a distinct isoform playing an important role in asthma and inﬂammation. This iso-
form causes the constriction of bronchioles in response to cysteinyl leukotrienes such as LTC4, thus
leading to asthma. It also induces neutrophilic inﬂammation by its recruitment in response to LTB4.
Importantly, 5-LOX activity is strictly regulated by 5-LOX activating protein (FLAP) though the dis-
tribution of 5-LOX in the nucleus. Currently, pharmacological drugs targeting FLAP are actively devel-
oping. This review summarized these functions of LOX enzymes under pathophysiological conditions in
mammals.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298
2. 15-Lipoxygenase (15-LOX). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298
2.1. ALOX15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299
2.2. Alox15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300
3. 15-Lipoxygenase, type B (15-LOX-2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
3.1. ALOX15B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
3.2. Alox15b . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
4. 12-Lipoxygenase (12-LOX). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
4.1. ALOX12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
4.2. Alox12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
5. 12-Lipoxygenase, 12R type (12R-LOX) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
5.1. ALOX12B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
5.2. Alox12b . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
6. Epidermal lipoxygenase 3 (eLOX-3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ma).
R. Mashima, T. Okuyama / Redox Biology 6 (2015) 297–3102986.1. ALOXE3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
6.2. Aloxe3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304
7. 5-Lipoxygenase (5-LOX) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
7.1. ALOX5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
7.2. Alox5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305Table 1
Properties of LO
Proteins
Human
Gene
Productsa
Expression
Mouse
Gene
Productsa
Expression
NA, not availab7.2.1. Inﬂammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
7.2.2. Atherosclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
7.2.3. Neuronal disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
7.2.4. Tumor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3058. 5-Lipoxygenase activating protein (FLAP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
8.1. ALOX5AP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
8.2. Alox5ap . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
9. Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
9.1. GSK2190915 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
10. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3061. Introduction
Lipoxygenases (LOXs) catalyze the oxygenation of poly-
unsaturated fatty acids such as arachidonic acid and linoleic acid
[1,2]. The oxygenated lipids initiate subsequent biological reac-
tions, activate cellular signaling mechanisms through speciﬁc cell
surface receptors, or are further metabolized into potent lipid
mediators. LOX can be found not only in mammals, but also in
plants. Historically, biochemical characterizations have been per-
formed mainly on soybean LOX isoforms. While the overall
structure of mammalian LOX enzymes seems to be similar, each
isoform has unique properties, such as substrate speciﬁcity (Ta-
ble 1, reviewed in [3]). In most cases, the structure depends on the
shape of the substrate cavity and the coordination of histidine
residues or alternatives to a non-heme iron atom at the catalytic
center [4,5]. Importantly, LOX enzymes require a lag period for the
activation of enzymes from an inactive ferrous form to an active
ferric form by either molecular oxygen or lipid hydroperoxides.
Enzymatic activity is also regulated by the N-terminal β-barrel
region of polypeptides, where this region has a similar amino acid
sequence to the C2-like domain; thus, Ca2þ-mediated activation
via interaction with the plasma membrane has been proposed.
Earlier studies have shown that LOX enzymatic activity can be
inhibited by phenolic antioxidants such as nordihydroguaiaretic
acid and caffeic acid, suggesting a beneﬁcial role of dietary poly-
phenol intake [6]. Alternatively, synthesized drugs for LOX are
relatively limited thus far. The 5-LOX inhibitor zileuton has been
accepted and used successfully for the control of asthma. Cur-
rently, inhibitors for 5-LOX activating protein are actively devel-
oped by many pharmaceutical companies [7]. These inhibitors
essentially modulate the transportation of 5-LOX from the nucleusX enzymes.
15-LOX 15-LOX-2 12-LOX
ALOX15 ALOX15B ALOX12
15S-HPETE 15S-HPETE 12S-HPETE
Leukocytes Epithelium, leukocytes Myeloids, skin, epithe
Alox15 Alox15b Alox12
12S-, 15S-HPETE 8R-HPETE, epoxyalcohols 15S-, 12S-HPETE
Leukocytes Skin, epithelium, leukocytes Platelet, skin, epitheli
le. aArachidonic acid as a substrate except eLOX-3 where 12R-HPETE asto the cytoplasm, leading to suppressive 5-hydro-
peroxyeicosatetraenoic acid (5-HPETE) production. This mode of
action of 5-LOX inhibitor is unique, and there are no similar reg-
ulatory mechanisms and drugs for other LOX isoforms.
From a genetic point of view, the alignment of LOX isoform
nucleotides encoded by arachidonate lipoxygenase (ALOX in hu-
mans and Alox in mice) genes has revealed that ALOX5 and other
ALOX genes have separate origins. The other ALOX genes seem to
have originated from fewer genes, as human ALOX genes are found
in a cluster in chromosome 17p13.1 and murine Alox genes are
found in chromosome 11 as active enzymes [8]. The expression
levels of ALOX genes are partially controlled by cytokines, such as
ALOX15, whose expression increases in response to Th2 cytokines.
ALOX enzymatic activity is also regulated by tissue distribution and
cell type. ALOX12B, ALOXE3, and ALOX15B are expressed mainly in
the skin and other epithelial cells, whereas ALOX15, ALOX12, and
ALOX5 are expressed in hematopoietic/immune cells. They are
involved in atherosclerosis, neuronal disorder, immune modula-
tion, skin diseases, and maintenance of the epithelium. The roles
of human enzymes (Table 2) seem to be slightly different from
what is expected from phenotypes of knockout mice (Table 3),
which shows that these oxygenated lipids are uniquely and ﬁnely
regulated in humans and mice.2. 15-Lipoxygenase (15-LOX)
15-LOX is a prototypical enzyme catalyzing oxygenation of
polyunsaturated fatty acids. Among various mammalian species,
rabbit reticulocyte LOX has been characterized from earlier studies
and often used as standard for biochemical assays. When the12R-LOX eLOX-3 5-LOX FLAP
ALOX12B ALOXE3 ALOX5 ALOX5AP
12R-HPETE Epoxyalcohols 5S-HPETE NA
lium Skin, epithelium Skin, epithelium Leukocytes Leukocytes
Alox12b Aloxe3 Alox5 Alox5ap
12R-HPETE Epoxyalcohols 5S-HPETE NA
um Skin, epithelium Skin, epithelium Leukocytes, epithelium Leukocytes
a substrate.
Table 2
Human diseases that potentially links to lipoxygenase genes.
Genes Atherosclerosis/heart disease Immune response Neurological
disorder
Cancer Skin disease Others
ALOX15 A near null mutant (T560M) in
coronary artery disease [140]
Rectal cancer [100] Bone mineral den-
sity↓[56,143–144]Colon cancer [141]
Adenoma recurrence [142]
Breast cancer [39]
Prostate cancer [12]
ALOX15B ↑ in carotid plaque with
thrombosis [43]
Esophageal cancer [35]
↑ in carotid lesion [32] Adrenocortical tumor [36]
Variants in coronary artery dis-
ease [145]
Breast cancer [39]
Epithelial tumors [37]
Prostate cancer cells [38]
Head and neck carcinoma
[40]
↑ in TAMs isolated from re-
nal cell carcinoma [42]
ALOX12 Variants in subclinical athero-
sclerosis [146]
Variants in Tox-
oplasmosis [147]
Bipolar disorder
[49]
Methylation in AML[61] Bone mineral den-
sity↓[54–57,150]
Schizophrenia [50] Esophageal squamous cell
carcinoma [64]
Fat mass↑[53]
Rectal cancer [100]
Adenoma recurrence [142]
Colorectal cancer [148]
E261R mutation
Breast cancer [48]
Colon cancer [47]
Colorectal cancer [65]
Colorectal adenoma [149]
ALOX12B ARCI [81–82,
94,151]
NCIE [84–
86]
ALOXE3 ARCI [82,
94,151]
NCIE [84,86]
ALOX5 Variants in atherosclerosis [152] Variants in asthma
[97,154,155]
Inverse correlation
↑ in atherosclerosis [153] Variants in AHR
[98,99]
Rectal cancer [100]
Variants in subclinical athero-
sclerosis [146]
Ovarian cancer [101]
Colon cancer [47]
ALOX5AP Variants in subclinical athero-
sclerosis [146]
Variants in asthma
[126,156]
Rectal cancer [100]
Adenoma [100]
AHR, airway hyperresponsiveness; AML, acute myeloid lymphoma; ARCI, autosomal recessive congenital ichthyosis; NCIE, nonbullous congenital ichthyosiform ery-
throderma; TAM, tumor-associated macrophages.
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tioxidants was explored, 15-LOX has been hypothesized to initiate
and/or promote atherosclerosis through low density lipoprotein
(LDL) oxidation. This is based on the “oxidative LDL theory” that
oxidation of lipids induces atherosclerosis and its inhibition by
antioxidants prevents atherogenesis. To initiate oxidation in vivo,
there must be some initiators for lipid peroxidation. One potential
candidate includes carbon-centered free radicals, which react with
molecular oxygen to give rise to peroxyl radicals. Since these ra-
dicals trigger oxidation of lipids continuously, therefore, genera-
tion of such free radical-generating initiators must be tightly
regulated in vivo. Lipid hydroperoxides generated from poly-
unsaturated fatty acids by LOX enzyme can induce this reaction
since these oxidation products further decompose into other freeradicals in the presence of metal ions. 15-LOX can be found in
macrophages and other immune cells as well as epithelial cells.
Human and mouse enzymes are known to be induced by Th2
cytokines such as IL-4 and IL-13 via STAT6-dependent manner
[9,10].
2.1. ALOX15
It is widely accepted that cyclooxygenase (COX) inhibitor non-
steroidal anti-inﬂammatory drugs (NSAIDs) induce colon cancer in
humans [11]. One suggested reason is that the balance between
COX and LOX determines tumorigenesis critically. Under low COX
activity, arachidonic acid released from cell membranes in re-
sponse to external stimuli is preferentially metabolized by LOX
Table 3
Phenotypes of LOX-deﬁcient mice.
Genes Atherosclerosis Immune response Neurological disorder Others
Alox15 ↓ in ApoE KO [19–21] LTC4↑[26] Peripheral diabetic neuropathy↓[163] Osteoclast development↑[28]
↓ in LDLR KO [22,23] Arthritis↑[157] Diabetic autonomic neuropathy-[163] Insulin resistance↓[164]
VSMC response↓[24] Schistosoma mansoni infection-[158] Angiogenesis↓[165]
Th1↓[159] Myeloid differentiation↓[27]
IL-12 ↓, TNF-α- [160] Erythrocyte development-[26]
Acute lung injury↓[161] Angiogenesis↓[166]
Phagocytosis↑[162] ER stress↓[167]
Hypertension↓[168]
Inﬂammatory neovascularization↓[169]
Nonalcoholic fatty liver disease↓[170]
Diabetes associated pp38 and pErk↓[171]
Obesity↓[29]
Ischemic cardioprotection↓[25]
Airway epithelial injury in asthma↓[172]
Alox15b Epidermal permeability barrier↓ [44]
Alox12 Platelet sensitivity↑[67] Carcinoma (B6/129)↓[68]
Papilloma (SENCAR)↓[68]
Basal transepidermal water loss↑[69]
Alox12b Skin barrier↓[87,95]
Ichthyosiform↑[88]
Aloxe3 Skin barrier↓[95]
Alox5 ↓ in LDLR KO [114] PAF-induced lethal shock↓[102,103] Anxiety-like behavior (C57BL/6)↑[117] Inﬂammatory neovascularization↓[169]
OVA-induced asthma↓[108] Synaptic dysfunction↓[119] Endotoxin-induced Hypoxic pulmonary
vasoconstriction↓[176]
Schistosoma mansoni infection↓[158] Anxiety-like behavior (B6/129)↓[175] ApcΔ468-induced intestinal polyposis↓[121–123].
Early female mortality (MRL-lpr/
lpr)↓[109]
Toxoplasma gondii elimination↓[107]
Tumor-inﬁltrating
macrophages↑[121]
OVA/alum-induced
Th2↓[159]
Peritonitis↓[105]
LTB4↓[173]
Acute pancreatits↓[104]
Borrelia burgdorferi elimination↓[106]
Histoplasma capsulatum
elimination↓[174]
Alox5ap ↓ in COX-2 KO [115] PAF-induced shock↓[127] Improved Alzheimer's disease-like
phenotype [133]
Zymozan-induced peritonitis↓[127] Anxiety-like behavior↑[134]
Collagen-induced arthritis↓[129]
Cerebral inﬂammation↓[128]
ApoE, apolipoprotein E; ARCI, autosomal recessive congenital ichthyosis; KO, knockout; LDLR, low-density lipoprotein receptor.
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(13S-hydroperoxyoctadecaenoic acid) generated from linoleic acid
induces apoptosis in colon cancer cells; thus, defective expression
of ALOX15 in colon cancers could promote tumorigenesis [11].
ALOX15 expression itself is controlled, at least in part, by the epi-
genetic process, as an alteration of methylation in the ALOX15
promoter has been observed in prostate cancer patients [12].
Furthermore, the expression of 15-LOX in epithelial cancer cells is
tightly regulated by additional mechanisms. As mentioned, STAT6
is a critical regulator of ALOX15 expression regulated by its phos-
phorylation and acetylation, as well as histone modiﬁcation
[13,14]. Recent studies have also shown the ALOX15 expression can
be modulated by the chromatin-dependent STAT6-independent
mechanism [15,16]. Biochemically, the produced 13 S-HPETE in-
teracts with PPAR-δ, followed by the induction of apoptosis priorto carcinogenic conditions [17]. The importance of 15-LOX-derived
metabolites has also been deﬁned by its aberrant failure in con-
ditional transgenic mice, expressing it in the mouse prostate, in-
ducing prostatic intraepithelial neoplasia once the apoptotic
function is dysregulated [18].
2.2. Alox15
Atherosclerosis is an inﬂammatory disease characterized by an
accumulation of lipid-loaded macrophages in blood vessels. Evi-
dence has suggested a close link between Alox15 expression and
atherosclerosis in the mouse, characterized mostly on the ather-
osclerosis-prone genetic background of mice lacking the ApoE and/
or LDL receptor [19–23]. In both cases, the initiation and/or de-
velopment of atherosclerosis depends on 15-LOX enzymatic
R. Mashima, T. Okuyama / Redox Biology 6 (2015) 297–310 301activity. Recent studies have suggested that atherosclerosis is in-
volved, at least in part, in sterile inﬂammation characterized by
augmented IL-1β and the activation of caspases. The accumulation
of lipids in blood vessels causes a failure of vascular function;
therefore, disruption of Alox15 shows impaired migration of vas-
cular smooth muscle cells [24]. In addition, ischemia-induced
cardioprotection plays an important role in maintaining proper
heart function. A previous study showed that Alox15 deﬁciency
caused its impairment after reperfusion-mediated preconditioning
by PKC activation in the heart [25]. These results suggest that this
enzyme might also contribute to the pathogenesis of cardiovas-
cular disease.
Lipid hydroperoxides, the primary reaction products of Alox15
from polyunsaturated fatty acids, readily induce oxidative stress
through their decomposition to free radicals. Thus, Alox15-deﬁ-
cient mice might produce less oxidative stress under physiological
conditions. However, Alox15-deﬁcient mice have shown an in-
crease in oxidative stress markers such as isoprostane 8-epi-
prostaglandin F2a in a zymosan-induced peritonitis model [26].
These apparently paradoxical results might be explained by the
concomitantly enhanced 5-LOX-, but not 15-LOX-, dependent
mechanism, which facilitates the accumulation of neutrophils by
5-HPETE and leukotrienes, thereby leading to enhanced oxidative
stress at the site of inﬂammation in Alox15-deﬁcient mice.
Accumulating evidence suggests that Alox15 is critically in-
volved in the regulation of cell differentiation. For example, the
development of hematopoietic stem cells into the myeloid lineage
is impaired in Alox15-deﬁcient mice [27]. Alternatively, the for-
mation of osteoclasts in Alox15-deﬁcient mice and mice treated
with enzymatic inhibitors has indicated its attenuation [28]. This
impaired bone-desorbing osteoclastogenesis is negatively regu-
lated by osteoblast formation, which derives from mesenchymal
stem cells. Given that this bone-absorption is impaired in Alox15-
deﬁcient mice, bone-generating osteoblast formation is likely to be
enhanced. In this case, adipocytes, which also stem from me-
senchymal stem cells, would be impaired. Consistent with this
speculation, Alox15-deﬁcient mice have displayed impaired obe-
sity [29], indicating a critical role of Alox15 in cell differentiation.3. 15-Lipoxygenase, type B (15-LOX-2)
15-LOX-2 shows higher similarity to 15-LOX, initially dis-
covered in the skin in humans [30]. Human 15-LOX-2 generates
12R-HPETE from arachidonic acid speciﬁcally, showing unusual
speciﬁcity for the regioisomeric lipid mediators in contrast to most
isozymes, which produce S-regioisomers. Furthermore, mouse
ortholog of 15-LOX-2 generates 8S-HETE and 8S-, 15S-diHPETE
from arachidonic acid, thus enzymologically murine Alox15b is
considered to be similar to human ALOX12 [31]. Due to this, there
are almost no overlapping diseases/phenotypes in the human and
mouse in this isoform.
3.1. ALOX15B
Although a link between atherogenesis and ALOX15 expression
has long been hypothesized, it is known that the expression of
ALOX15B in human carotid plaque macrophages is higher com-
pared to ALOX15 [32,33]. An in vitro experiment of ALOX15B si-
lencing reported an attenuated lipid accumulation in human
macrophages, indicating that it is functional for lipid uptake into
the cells [34]. Thus, it is suggested that ALOX15B plays an im-
portant role in the initiation and development of atherosclerosis in
humans.
Several studies have shown the downregulation of ALOX15B in
epithelial tumors, suggesting that ALOX15B has an antiproliferativerole [35–40]. This reduction of 15-LOX-2 in tumor cells was re-
stored by an inhibitor for COX enzyme, demonstrating that its
expression is negatively regulated by prostaglandins, at least in
part [35]. PPAR-γ, a nuclear receptor regulated by endogenous LOX
products, was upregulated in some epithelial tumors, suggesting
that the downregulation of ALOX15B is autonomously controlled
by PPAR-γ in epithelial cancer cells [37]. In prostate epithelial cells,
ALOX15 expression is positively regulated by transcription factor
Sp1, whereas transcription factor Sp3, which is closely related to
Sp1, negatively regulates its expression, suggesting that ALOX15B
expression is critically regulated by multiple regulators [41]. Apart
from epithelial cells, a separate study demonstrated increased
ALOX15B expression in tumor-associated macrophages from renal
cell carcinoma, suggesting that ALOX15B expression is distinctly
regulated in epithelial cancer cells and macrophages [42]. Similar
to tumor-associated macrophages, the upregulation of ALOX15B in
carotid plaque macrophages has also been described [32,43].
3.2. Alox15b
There are a limited number of studies involving Alox15b. In
chimeric mice transplanted with Alox15b-silenced bone marrow
cells in mice lacking LDL receptor showed defective atherogenesis,
suggesting that 15-LOX-2 is required in the murine atherosclerotic
model [34]. As mentioned previously, the enzymatic action of
murine 15-LOX-2 preferentially generates 12S-HPETE rather than
15S-HPETE from arachidonic acid, suggesting that mouse Alox15b
and human ALOX12 have similar roles in vivo. The skin of Alox15b-
deﬁcient mice has been shown to display an ichthyosiform ap-
pearance, as in Alox12b- and Aloxe3-deﬁcient mice [44]. This ex-
ample clearly shows that the skin phenotype found in Alox15b-
deﬁcient mice seems to require speciﬁc oxidation products from
polyunsaturated fatty acids. Furthermore, this result suggests that
Alox15b could be a functional alternative for Alox12b and Aloxe3.4. 12-Lipoxygenase (12-LOX)
12-LOX enzymes derived from ALOX12 in humans and its
murine ortholog Alox12 (also known as platelet-typed 12S-LOX)
produce 12S-HPETE from arachidonic acid. These enzymes are
expressed in leukocytes in humans and in platelets, mega-
karyocytes, and skin in mice [45,46]. Genetic studies have sug-
gested that ALOX12 gene polymorphisms are associated with
cancers [47,48], neurological disorders [49,50], hypertension
[51,52], fat mass [53], and bone mineral density [54–57]. The
mechanism of regulation of 12-LOX expression has been studied in
several models. The ALOX12 promoter region contains at least four
binding sites for RUNX1, leading to its suppressive effect in human
erythroleukemic cells [58]. Alox12 expression is also regulated by
transcription factor p63 in the skin, which plays a key role in the
development and terminal differentiation of the epidermis [59].
Similar to other isozymes, human 12-LOX has a catalytic domain in
the C-terminal. Truncation of the N-terminal domain (which needs
to be explored in terms of function) decreases its enzymatic ac-
tivity at approximately 20% without altering substrate speciﬁcity
[60].
4.1. ALOX12
Since the discovery of the high expression of LOX in platelets,
the mechanism of its expression has been studied in detail. A
previous study reported that ALOX12 expression was attenuated in
platelets by the haplodeﬁciency of RUNX1, a hematopoietic tran-
scription factor associated with familial thrombocytopenia, plate-
let dysfunction, and a predisposition to acute leukemia in patients
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epigenetically, as indicated by the increase in DNA methylation of
ALOX12 genes in myelodysplastic syndrome and acute myeloid
leukemia patients with megakaryocytic dysplasia [61,62]. It has
been suggested that ALOX12 is associated with diminished bone
mineral density as well [54–57]. Given that 12-LOX produces en-
dogenous lipid ligands for nuclear receptors, such as PPAR-γ,
which facilitate adipocyte differentiation from mesenchymal stem
cells, the number of osteoblasts decreases, followed by impair-
ment of bone mineral density [55].Fig. 1. A. Schematic representation of transepidermal water loss (TEWL) from the skin. B
over corniﬁed envelop (CE) on corneocyetes.An earlier study suggested that the 12-LOX-mediated pathway
is associated with the risk of colorectal cancer [63]. The best-stu-
died example includes mutation of E261R (835A4G), which
causes an increase in 12-LOX activity, with a potential link to
esophageal squamous cell carcinoma [64]. This mutation has also
been associated with colorectal cancer [47,65] and breast cancer
[48]. An in vitro and in vivo study has shown that 12-LOX plays a
role in the proliferation and antiapoptosis of hepatocellular cells,
suggesting that this carcinogenic function of ALOX12 requires en-
dogenously generated lipid mediators [66].. Reaction of 12R-LOX and eLOX-3. C. Development of corneocyte-lipid envelop (CLE)
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Consistent with the expression of ALOX12 in the platelets of
humans, mice lacking Alox12 have shown increased platelet sen-
sitivity and mortality due to thrombosis in response to the ad-
ministration of adenosine diphosphate, whereas aggregation and
secretion in response to most agonizts seemed normal [67]. Alox12
deﬁciency has led to a reduced incidence of carcinoma in a
C57BL6/129 genetic background and of papilloma in a tumor-
sensitive SENCAR genetic background, showing that Alox12 is in-
volved in tumorigenesis in the skin in a context-dependent man-
ner [68]. Most notably, Alox12 deﬁciency has caused basal trans-
epidermal water loss in the skin with unaltered inﬂammatory
responses in Alox12b- and Aloxe3-deﬁcient mice [69]. This ﬁnding
suggests that Alox12 has a critical role in the maintenance of the
skin barrier in association with other isoforms, as explained in
detail later.5. 12-Lipoxygenase, 12R type (12R-LOX)
In humans, 12R-LOX has been detected in keratinocytes, tonsil
squamous epithelial cells, bronchial epithelial cells, and psoriasis
scales, as well as in B cells [8,70–74]. In mice, its expression has
been induced at embryonic day (E) 15.5 in the epidermis, nasal
epithelium, and surface of the tongue, suggesting that 12R-LOX is
required for the proper development of neonates [71].
The physiological role of 12R-LOX is rather speciﬁc, in con-
junction with its limited expression proﬁle in epithelial cells. The
best-characterized example is the skin. The important physiolo-
gical role in the skin is to maintain appropriate moisture by pre-
venting unnecessary water evaporation through epithelial cells,
called transepithelial water loss (TEWL) (Fig. 1A). TEWL results in a
loss of water from the skin, leading to excessively dry skin, as
found in ichthyosis. In humans, this inherited disease is known as
autosomal recessive congenital ichthyosis (ARCI) (MIM#s 190195,
242100, 242300). Biochemically, 12R-LOX reacts readily with li-
noleate rather than arachidonate to produce 9R-HPODE (Fig. 1B).
This hydroperoxide is converted into its associated epoxide deri-
vatives through the isomerase activity of eLOX-3 [75]. In the skin,
the best substrate for these enzymes is linoleate, which is ester-
iﬁed with ω-hydroxylated sphingolipids, usually found outside
corneocytes during the immature stage of skin development
(Fig. 1C). As mentioned previously, this esteriﬁed linoleate is fur-
ther converted into oxygenated linoleate, followed by elimination
from sphingolipids by hydrolysis. The newly formed ceramide is ω-
terminally hydroxylated; therefore, it is subsequently linked
covalently to a carboxyl acid moiety of glutamine in corniﬁed
envelope (CE) proteins. The established lipid layer is called a cor-
neocyte-lipid envelope (CLE), and it plays a crucial role in holding
water in the hydrophobic group, in ceramides in the CLE. The
completion of CLE formation requires transglutaminase-1, which
catalyzes the cross-linking of the ceramides with the carboxylic
acid in the side chain of glutamate in CE proteins, as many mu-
tations of 12R-LOX enzymes cause ARCI in humans [76]. Mice
lacking the transglutaminase-1 gene have consistently exhibited
defective skin formation and high TEWL [77]. Both enzymes act
critically prior to this transglutamination, as previous observations
have suggested that a deﬁciency of 12R-LOX, as well as eLOX-3,
causes failure of the skin barrier due to defective formation of
enzymatic lipid oxidation products [78–80].
5.1. ALOX12B
Genetic failure of the above process leads to ARCI, a hetero-
geneous skin disease characterized by rough and scaly skin, with aprevalence of one in 200,000 newborns throughout the world
[81–86]. The affected skin generally improves during either
childhood or puberty, and these patients have a normal life span.
Among various ARCI diseases, ALOX12B is mainly, but not solely,
involved in nonbullous congenital ichthyosiform erythroderma.
Mutations, mostly found as missense, termination, and frameshift
in ALOX12B, are widely found in its entire molecule, involving both
in a C-terminal catalytic domain and an N-terminal β-barrel
structure [82]. Some mutants have lost enzymatic activity, as
conﬁrmed by biochemical assays.
5.2. Alox12b
Disruption of the Alox12b gene in the murine model provides
an effective means of studying human ichthyosis. Alox12b-deﬁ-
cient mice suffer postnatal death characterized by a severely im-
paired barrier function of the skin [87]. This defective epidermal
barrier appears around E17.5 in wild-type (WT) controls, prior to
which the expression of Alox12b reaches its maximal level begin-
ning at E15.5 and continues after birth. Thus, there is a strong
correlation between Alox12b expression and the formation of
functional epidermis.
A study using skin transplantation from Alox12b-deﬁcient
neonates into nude mice revealed ichthyosiform formation, typi-
cally characterized by a thickening of the epidermis and severe
hyperkeratosis, with a phenotype similar to that of patients with
ALOX12B mutations in the grafted mice [88]. Essentially, the skin
grafted from the neonates became thicker than that from the WT
controls, with a hyperplastic histology displaying epidermal
acanthosis and severe hyperkeratosis. Further investigation of this
hyperkeratosis by electron microscopy revealed that the stratum
corneum of skin grafted from Alox12b-deﬁcient mice was abnor-
mally overlaid, indicative of aberrant proliferation. In addition,
both the size and number of keratohyaline granules increased,
indicating hypergranulosis in mutant skin grafts. Functional assays
that measured TEWL identiﬁed a marked increase in the skin from
the neonates, as well as a marginal but signiﬁcant increase in
mature skin grafted in these mice, demonstrating that Alox12b
plays a critical role in the maintenance of barrier function in the
skin (Fig. 1A). Among genetically manipulated mice with defects in
barrier function in the skin, such as KLF4- and Claudin-deﬁcient
mice [89,90], Alox12b-deﬁcient mice displayed an extremely de-
fective phenotype in epidermal barrier function, but not in tight
junctions.6. Epidermal lipoxygenase 3 (eLOX-3)
As mentioned previously, the conversion of linoleoyl ceramide
in CLE into CE plays a crucial role in the proper maintenance of
epidermal barrier formation. The eLOX-3 enzyme plays a major
role in the second step, which involves the conversion of 9R-
HPODE esteriﬁed with ω-hydroxyacyl-sphingosine into its related
epoxylated derivative (Fig. 1B) [91–93]. Biochemical reactions
catalyzed by eLOX-3 are essential, and their failure leads to ARCI.
6.1. ALOXE3
Genetically, many mutations in ALOXE3, together with ALOX12B,
have been found in ichthyosis [81–84,86,94]. The outcome of
disease in ALOXE3 variants seems to be similar to that found in
ALOX12B variants, showing clearly that this sequential oxidation by
ALOXE3 and ALOX12B are equally important. As a substrate, it is
known that eLOX-3 favors oxygenated lipids like 12R-HPETE rather
than unoxidized compound such as arachidonic acid (Fig. 1B).
Other than ARCI, other diseases associated with ALOXE3 variants
Fig. 2. Formation of resolvins from eicosapentaenoic acid (20:5).
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6.2. Aloxe3
A previous study showed that Aloxe3-deﬁcient mice also ex-
hibit a similarly severe ichthyosis phenotype with the loss of
covalently bound ceramides and impaired CLE development [86].As expected from its hepoxilin synthase activity of eLOX-3, in vivo
results also showed a marked reduction of its metabolites in the
skin. Similar to Alox12b-deﬁcient mice, Aloxe3-deﬁcient mice dis-
played a postnatal lethal phenotype [95].
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5-LOX plays an important role in the control of asthma. Under
asthmatic conditions, activated immune cells ﬁrst produce ara-
chidonic acid by an enzymatic action of phospholipase A2 from the
plasma membrane, followed by 5-HPETE production through the
5-LOX enzyme. The produced 5-HPETE then converts into leuko-
trienes that have a potent biological effect on the constriction of
bronchioles through cysteinyl leukotriene receptor 1, which is
expressed exclusively onto bronchiolar smooth muscle cells, but
not epithelial cells [96]. Conversely, cysteinyl leukotriene receptor
2 is expressed strongly in pulmonary interstitial macrophages and
weakly in smooth muscle cells.
7.1. ALOX5
The expression of the ALOX5 gene is transcriptionally regulated
at a basal level and regulated by external stimuli such as Ca2þ .
Numerous agents have been developed as antiasthmatics. A potent
LOX-5 inhibitor zileuton introduced in the United States blocks a
considerable amount of cysteinyl leukotriene production for a
short period of time. Although the prevalence is low, a genetic
E254K (760G4A) mutation in ALOX5 has been reported in
bronchiolar asthma patients [97]. This mutation causes an altera-
tion in the electronic charge of the C-terminal catalytic domain
from negative to positive, implicating defective changes in enzy-
matic activity and protein interaction. Mutations in the Sp1
binding site in the ALOX5 promoter has been associated with air-
way hyperresponsiveness, but not with asthma [98,99]. Some
evidence suggests that low 5-LOX expression in tumors found in
humans might lead to greater 15-LOX expression followed by
cancer formation through impaired apoptotic activity [47,100,101].
7.2. Alox5
7.2.1. Inﬂammation
As mentioned previously, immune cells express leukotriene
receptor 1 and 2 as well as cysteinyl leukotriene receptor 2; as
such, the role of Alox5 could account for the migration of these
immune cells. As expected, neutrophilic inﬂammation is one of the
apparent phenotypes in Alox5-deﬁcient mice. These mice have
been shown to be resistant to anaphylaxis induced by platelet-
activating factor (PAF), showing that Alox5 seems to be closely
involved in this process [102,103]. Similarly, Alox5-deﬁcient mice
exhibit a suppressed response to chemically induced local in-
ﬂammation [104,105]. These mice are also susceptible to Borrelia
burgdorferi-induced arthritis [106]. In this study, the authors
showed that enzymatic activity of 5-LOX is not required for the
initiation of infection, but it is required for earlier joint swelling
and retarded arthritis recovery, suggesting a potential increase in
the accumulation of neutrophils. Similarly, in a Toxoplasma gondii
infection model, Alox5-deﬁcient mice exhibited suppressed leu-
kotriene A4 production and increased interleukin-12 and inter-
feron-γ production, followed by an increase in mortality rate due
to marked encephalitis [107]. Such altered cytokine production
seems to be explained, at least in part, by impaired neutrophilic
inﬂammation.
In an ovalbumin-induced asthma model, Alox5-deﬁcient mice
exhibited a suppressed methacholine-induced response to airway
hyperresponsiveness with impaired eosinophilic inﬂammation in
the lung [108]. Thus, the production of lipid products from 5-LOX
plays an important role under physiological conditions, and its
level is tightly regulated by the balance between LOX and other
enzymes, such as COX, as shown in an earlier study. Another study
reported an increased mortality rate in Alox5-deﬁcient male mice
with an autoimmune-prone MRL-lpr/lpr genetic background,raising the possibility that an enhanced renal autoimmune in-
ﬂammation could be involved in this process [109].
Recently, the roles of oxidation products derived from eicosa-
pentaenoic acid (20:5) and docosahexaenoic acid (22:6) have been
studied extensively (Fig. 2). As seen in their chemical structures,
20:5 and 22:6 have four and ﬁve bisallylic carbon atoms, respec-
tively, in their molecules, providing a variety of oxidation products
through free radical-mediated mechanisms. For example, 20:5 is a
primary substrate for conventional LOX enzymes such as 15-LOX,
12-LOX, and 5-LOX. In addition, 18-hydroperoxy-5,8,11,14,16-eico-
sapentaenoic acid (18-HPETE), a free radical-mediated oxidation
product of 20:5, can be further metabolized by 5-LOX to produce a
novel class of oxidation product collectively called resolvins (Fig. 2)
[110,111]. Emerging evidence has shown that resolvins assist in
terminating inﬂammation through speciﬁc GPCR ChemR23 at nM
concentrations in vitro [112]. The formation of resolvins seems to
be critically regulated by local O2 concentration, as well as the
expression and activity of multiple LOX enzymes, both of which
inﬂuence the ﬁnal yield of resolvins from its initial substrate 20:5.
Due to its anti-inﬂammatory function, whether these oxidized li-
pids might modulate the functions of microRNAs is under in-
vestigation [113].
7.2.2. Atherosclerosis
Apart from reactions in asthma and neutrophilic inﬂammation,
there is some research showing that 5-LOX plays a key role in the
initiation and/or development of atherosclerosis. Impaired ex-
pression of functional 5-LOX in LDL receptor-deﬁcient mice has
revealed suppressed atherogenesis, suggesting that 5-LOX plays a
causative role in this disease [114]. Consistently, another athero-
sclerotic model induced by COX-2 disruption attenuated disease
formation in Alox5-deﬁcient mice [115]. Given that LOX-15 is in-
volved in atherosclerosis, these studies provide examples that
atherosclerosis can be induced by lipid peroxidation products
formed from any isoforms. This ﬁnding is entirely consistent with
observations indicating that antioxidants generally exhibit pro-
tective effects in experimental models.
7.2.3. Neuronal disorder
Alox5 is known to be highly expressed in neuronal tissue, par-
ticularly in Alzheimer’s disease; thus, its role in neuronal disorders
has been actively characterized [116]. A recent study reported that
aged female Alox5-deﬁcient mice exhibited protective effects
against anxiety-like behavior on a C57BL/6 genetic background,
raising the possibility that Alox5 could modulate neuronal function
[117]. A subsequent study using a transgenic mouse model of
Alzheimer’s disease demonstrated the efﬁcacy of a 5-LOX inhibitor
zileuton and hypothesized that Alox5 could facilitate the initiation
or progression of this disease [118]. Using such a disease model,
Alox5 deﬁciency consistently improved disease phenotypes [119].
7.2.4. Tumor
Colorectal cancer is often caused by mutation of the tumor
suppressor Adenomatous polyposis coli (APC) gene. Among many
mouse models generated by Apc mutations, ApcΔ468 mice speciﬁ-
cally bear a truncated Apc gene that develops severe polyposis by
four months [120]. Interestingly, immunohistochemistry showed
an increase in Alox5 expression in ApcΔ468 mice, suggesting that
LOX-5 might contribute to tumorigenesis in colorectal cancer
[121–123]. Mast cells play an important role in the development of
colorectal cancer in this animal model, as they induce epithelial
proliferation [122]. Consistently, the number of mast cells in-
creased in APCΔ468 mice compared to WT controls. In this model, a
deﬁciency in Alox5 led to impairment, implying that LOX5 acts as
an important role in colorectal tumorigenesis [122].
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FLAP is a small protein that activates 5-LOX through protein
interaction. The formed complex of 5-LOX and FLAP in the nucleus
efﬁciently generates 5-HEPE from arachidonic acid, which is sub-
sequently converted into various leukotrienes. FLAP protein stays
on the nuclear membrane and acts as a transporter for 5-LOX.
FLAP expression is limited in myeloid cells.
8.1. ALOX5AP
Drugs targeting FLAP protein have been actively developed in
humans. DG-031 (veliﬂapon, BAY x 1005), ﬁrst licensed by DeCode
Genetics and then developed by Bayer, is one example. This
compound also reduces the incidence of ischemic myocardial in-
farction by reducing LTB4 production [124]. A recently developed
AM-103/GSK2190914 was designed based on the three-dimen-
sional structure of FLAP protein [125]. In asthma, two intronic
single-nucleotide polymorphisms have been associated with
ALOX5AP, suggesting that these mutations can be used for diag-
nostic markers [126].
8.2. Alox5ap
Alox5ap-deﬁcient mice exhibited unique phenotypes similarly
observed in Alox5-deﬁcient mice, such as an impaired response to
PAF-induced anaphylaxis and zymosan-induced peritonitis [127].
In a collagen-induced arthritis model, Alox5ap-deﬁcient mice dis-
played impaired arthritis, whereas the accumulation of antibody
against collagen remained unchanged, suggesting that 5-LOX po-
sitively regulated inﬂammation without affecting the immune
response. In a cerebral artery occlusion model, disruption of the
Alox5ap gene caused impaired median infarct size and a better
functional score, demonstrating that FLAP protein positively reg-
ulates cerebral inﬂammation [128]. The expression of Alox5ap is
independent of the expression of 5-LOX. Alox5ap induces 12S-
HETE production in the 12-LOX-induced signaling pathway, sug-
gesting that 5-HPETE or downstream leukotriene metabolites
might be involved in this process [129].
In atherosclerosis, FLAP inhibitor MK-886 and BAY x 1005 ef-
fectively attenuated disease formation in mice lacking ApoE and
LDL receptors [130,131]. Similarly, another atherosclerotic model
developed by transgenic mice expressing a dominant negative
form of TGFβ receptor II in ApoE-deﬁcient mice was suppressed by
MK-886 [132]. These examples strongly suggested that FLAP pro-
tein is required for atherogenesis in these mouse models. Con-
sistently, Alox5ap-deﬁcient mice exhibited attenuated disease
formation in an experimental model generated by Cox-2-deﬁcient
mice [115].
Alox5ap-deﬁcient mice displayed an improved Alzheimer’s
disease-like phenotype [133] and an apparent increase in anxiety-
like behavior in aged mice [134]. These results supported the
phenotype of Alox5-deﬁcient mice, showing that both 5-LOX and
FLAP mutually and collaboratively play critical roles in the leuko-
triene pathway in neurological disorders.9. Clinical Trials
There are many studies reporting synthesis and characteriza-
tion of lipoxygenase inhibitors (reviewed in [135,136]). Generally,
substances sharing similarity to either lipids or phenolic anti-
oxidants have lower inhibitory activity for LOX enzyme. Further-
more, due to the presence of multiple isoforms, the development
of selective inhibitor seems to be challenging. Therefore, there is a
limited number of successful drugs that can be used fortherapeutic purposes. One clinically applicable example includes
zileuton that acts as anti-asthmatic agent by inhibiting 5-LOX.
Apart from direct regulation of enzymes, there are some studies
targeting FLAP for modulating 5-LOX under pathophysiological
conditions in clinical trials.
9.1. GSK2190915
This is a FLAP inhibitor that inhibits the production of LTB4 and
other cysteinyl leukotrienes. The results of Phase I study showed
that there was no clear difference in adverse events between
placebo and drug-treated subjects in Western Europe (EUR-
DACT2007-00484872) and Japan (NCT00955383) [137]. Plasma
concentration of GSK2190915 reaches maximal at two hours after
oral administration. Consistently, LTB4 production in drug-treated
subjects was signiﬁcantly impaired (EC50 in plasma is approxi-
mately 85 nM). Its beneﬁcial effect is proven in adults and ado-
lescents with persistent asthma (NCT01147744) [138]. Comparison
between GSK2190915 and established asthma treatment such as
montelukast and the inhaled corticosteroid ﬂuticasone propionate
revealed that GSK2190915 30 mg once daily has similar effect
compared to montelukast 10 mg once daily as assessed by forced
expiratory volume in 1 s (FEV1), a widely used measure for asthma
evaluation. A subsequent study reported that GSK2190915 50 mg
daily showed clear attenuation in early asthmatic response in-
duced by inhaled allergens in a placebo-controlled double-blind
randomized study in UK (NCT00812773) [139].10. Conclusions
The physiological roles of LOX enzymes have been studied ex-
tensively, due to the close link between them and various diseases.
Apparently, the best characterized example includes the relation
between 5-LOX and asthma, because cysteinyl leukotriene re-
ceptor 1, a GPCR activated by leukotrienes produced by 5-LOX, is
widely expressed on bronchiolar smooth muscle cells. Genetically,
both ALOX12B and ALOXE3 play a critical role in the development
of ichthyosis through TEWL. In humans, some mutations in
ALOX12 are found in tumor cells, suggesting this isoform might
have anti-tumor effect. An increased expression of LOX enzymes in
response to Th2 cytokines has been well established; how their
expression is controlled and its consequences need to be in-
vestigated in the future.Acknowledgment
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